News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis AG Says Glivec Misses Main Goal in Study
June 13, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Novartis AG's cancer drug Glivec failed to meet its main target in a late-stage study of patients with chronic myeloid leukaemia (CML), the Swiss drugmaker said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
Novartis
MORE ON THIS TOPIC
Alzheimer’s disease
Merck axes Alzheimer’s study, adding to partner Neuphoria’s mounting woes
July 2, 2026
·
2 min read
·
Tristan Manalac
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
·
2 min read
·
Gabrielle Masson
Approvals
Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment
July 1, 2026
·
2 min read
·
Heather McKenzie
Neuropsychiatric disorders
Vistagen in freefall as social anxiety drug fails Phase 3
July 1, 2026
·
2 min read
·
Tristan Manalac
